Joe: The largest restructuring in the history of Novartis; 2014 - 2015

That is the message coming from leaks from Basel to the analysts and I-Bankers. Novartis' guidance will be that Gross Rev $'s will continue to increase and Net Rev $'s will be preserved by taking out costs thus significantly improving productivity.

 

Pharma Sales - wave after wave of lay-offs in the last few years. Signs are that there are more to come.

Vaccines - history. Just a matter of time.

Development - Big announcements Monday with rumor of more to come over the summer.

NIBR - start in May rolling thru Sept.

 

Joe Jimenez Novartis' Jack Welch.

 

The board intends to remake all of Novartis into a model that all of pharma will have to emulate.

 

Regarding vaccines, how in the world is that operation still humming along? Amazing the plug hasn't already been pulled.

 

And there is a thread here on CP with over 250,000 views that documents what a bunch of over paid idiots they are. A reality "Bozo Show". Honey Boo-Boo would have been a rapidly promoted high-pot there!

 

"If you throw a frog into a boiling pot of water, he will jump back out. If you put him into the pot before you turn up the heat, he will stay there until he boils."

We don't yet realize it but this will be apparent once it is over.

 

This is how vulture capitalism works. They shrink and shrink the company in order to make profits look good. But...what is the reality?

 

Depending on where the shrinkage is happening. The Hem/Onc BDU has waaay tooo many sales reps. Half of them stay home - the other half working complain about bumping into one another.

 

This is very naive - ⅔ of all of the Sales Reps will eventually be reduced.

 

Ask Developement

 

The flame is being turned up.

 

From FierceBiotech


March 24, 2014 | By John Carroll




At Novartis, only the top executives are allowed to discuss R&D strategy in any kind of a meaningful way. So when they talk, everyone--including the company's big research staff around the world--pays very, very close attention.

So listen up: The new chairman at Novartis ($NVS), Joerg Reinhardt, sat down with The Wall Street Journal to review the company's careful restructuring--R&D is being concentrated in Basel, Shanghai, Boston and La Jolla, CA--and committed Novartis to maintain research spending at its current level near the $10 billion mark. That mark falls just behind Roche's research budget, the top R&D spender in the biopharma world with a 2013 budget of $10.23 billion. And it must be particularly welcome news in La Jolla.
Reinhardt says R&D spending will remain level at a time many pharma rivals are cutting back. And everyone in the company should expect to see the work consolidated in key regions, something that is likely to reassure workers in designated areas while raising fears for everyone outside the protected zones.

"A larger group of people benefiting from the infrastructure that's been created at a research place is a better approach than having small groups with limited infrastructure spread around the world," Reinhardt told the Journal. And it gives the giant a chance to work more closely with the academics in those areas.
The new strategy--overseen by a unique special committee--has already led to some significant alterations, especially with the closure of its research unit in Horsham, U.K., and some shifting of jobs and personnel in the U.S. The company has reportedly laid off thousands of staffers in recent months, including 500 at its home base in Basel.
This strategy falls right in line with the brave new world of Big Pharma as defined by most of the top companies these days. That hub strategy inspired AstraZeneca to concentrate its forces in Cambridge, U.K., sacrificing Alderley. Sanofi ($SNY), largely foiled in an attempt to reorganize R&D in France, has been shifting into Boston. Pfizer ($PFE) and Roche ($RHHBY) have both eliminated big outlying research posts in major retrenching efforts.

 

So let me summarize, "the NIBR strategy has been so successful we will do more of it or basically, double down on a bet that has so far been a loser".

"please continue Governor . . . . . . "

Gawd this is great, as the profits are drained from this bloated pig of an organization the head pig want to waste more.

hahahahahaahahaha - this will save research jobs . . . . for the near future until it continues to be the hot streaming turd that is has been since it was conceived!

 

Interesting read